(PRINCETON, NJ, March 24, 2008) New BARACLUDE (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-nave patients through five years of treatment. In the nucleoside-nave chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108). Through five years of treatment, the cumulative probability of developing mutations in the virus that confer resistance to BARACLUDE (also called genotypic resistance) was 1.2 percent. Bristol-Myers Squibb Company (NYSE: BMY) announced the results at the 18th Conference of the Asia-Pacific Association for the Study of the Liver (APASL) in Seoul, Korea.
In lamivudine-refractory patients who received BARACLUDE after treatment with lamivudine failed, the cumulative probability of genotypic BARACLUDE resistance was 51 percent through the fifth year. This finding is consistent with prior observations that the pre-existence of lamivudine-resistant mutations results in an increase in the rate of BARACLUDE resistance.
Many chronic hepatitis B patients require long-term treatment. Unfortunately, the initial benefits of therapy can be lost after the development of resistance. These five-year BARACLUDE data that demonstrate long-term minimal resistance at 1.2 percent in nucleoside-naive patients can be of great importance for patients, said Professor Ching-Lung Lai, Chief, Division of Gastroenterology and Hepatology, University of Hong Kong.
Drug resistance occurs when the hepatitis B virus (HBV) mutates, thereby avoiding the effects of the medication. This can decrease the efficacy of the current medication and may compromise future treatment options. To date, studies have shown that multiple mutations are required to develop BARACLUDE (entecavir) resistance.
These long-term BARACLUDE data continue to support the observations seen in the first years of treatment and are reflective of BARACLUDEs high genetic barrier to
'/>"/>
| Contact: Hilary Mra mrah@ruderfinn.com 212-593-6414 Ruder Finn Public Relations Source:Eurekalert |
Related biology news :
1. Researchers discover new strategies for antibiotic resistance
2. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
3. Binghamton University researchers investigate evolving malaria resistance
4. Drug could improve pregnancy outcomes in wider range of women with insulin resistance
5. Feline virus, antiviral drug studied to understand drug resistance
6. Manure management reduces levels of antibiotics and antibiotic resistance genes
7. High degree of resistance to antibiotics in Arctic birds
8. Gene that controls ozone resistance of plants could lead to drought-resistant crops
9. First orchid fossil puts showy blooms at some 80 million years old
10. ESA celebrates 100 years of insect science journals
11. Researchers detect hint of oxygen 50 to 100 million years earlier than first believed
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |